SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Vertex Pharmaceuticals (VRTX)
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
1169 64 0 VRTX
Emcee:  David Lieberman Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
944You had previously taken the position, based on Arm D data, that SVR would be inCasaubon-7/24/2007
943<i>>I take it you are backing off your position of 35% SVR based on ITTDewDiligence_on_SI-7/24/2007
942DD, I take it you are backing off your position of 35% SVR based on ITT from yoCasaubon-7/24/2007
941Roughing out the Telaprevir SVR rate: tinyurl.comDewDiligence_on_SI-7/24/2007
940The non-Ende part of ML's biotech team is into option strategies: <i>tom pope-7/5/2007
939Vertex Pharmaceutical's Hepatitis Drug Proves Effective, But Path To Market LJM-5/31/2007
938Vertex Slips After Analyst Downgrades, Predicting FDA Request for More Data on Ttom pope-4/23/2007
937I really like this company's drug pipeline. Looking for the stock to trade iTech Master-4/18/2007
936Vertex Hep-C Drug Shows Promise By Adam Feuerstein Senior Writer 4/16/2007 7:2Doc Bones-4/16/2007
935Re: VRTX CC from EASL After all the buildup, EASL concludes not with a bang butDewDiligence_on_SI-4/14/2007
934Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigationalsim1-4/14/2007
933Deleted.rkrw-4/11/2007
932<i>Reproduction of the table mentioned in post 931 Jason</i> <pretnsaf-4/11/2007
931<i>Abstracts from EASL. I found a sixth poster presentation that has VX95tnsaf-4/11/2007
930Vertex Pharmaceuticals Announces New Data for Investigational HCV Protease InhibLJM-4/11/2007
929Are these guesses for 12 weeks of 950 with soc? I'd be surprised and impressrkrw-4/11/2007
928I don't see anything in there about the PROVE trial results being disclosed OpusX-4/11/2007
927Presentations at EASL that have "VX-950" in the title or "Vertex&tnsaf-4/11/2007
926So I would think that a strong PCR negative rate around 75% will take the stock idos-4/6/2007
925<i>Some important upcoming dates</i> Vertex Pharmaceuticals Announctnsaf-4/5/2007
924I am not sure what I think of measuring this on ITT basis - in long run, yes. BRobohogs-4/4/2007
923Well, I'm an IDIX holder, too, and I said "might be". What's tuck-4/4/2007
922Biased? LOL :-)DewDiligence_on_SI-4/4/2007
921That's certainly a reasonable way to play it, with less risk/reward. "tuck-4/4/2007
920I like the short puts better here personally. Lot of volatility in them and harRobohogs-4/4/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News